Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on therapies for central nervous system (CNS) disorders, has announced the successful completion of the first-in-human Phase 1 clinical study of SUVN-I6107, a novel muscarinic M1 positive allosteric modulator (M1-PAM). The study met its primary objectives and demonstrated favorable safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, supporting the advancement of the candidate into Phase 2 clinical development.
The randomized, double-blind, placebo-controlled Phase 1 trial evaluated SUVN-I6107 in healthy volunteers through both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The study enrolled a total of 64 participants and included assessments designed to evaluate safety, tolerability, drug exposure and central nervous system activity.
According to the company, SUVN-I6107 demonstrated a favorable safety profile across all evaluated dose levels. No serious adverse events or deaths were reported during the study, and no participant discontinued treatment due to adverse events. All treatment-emergent events observed were mild to moderate in severity and resolved before study completion.
The compound also exhibited predictable and dose-proportional pharmacokinetics, with increasing exposure levels corresponding to higher doses. The study showed no clinically meaningful differences in drug behavior between male and female participants, suggesting that gender-based dose adjustments may not be necessary in future studies. Food intake also did not significantly affect drug exposure, supporting flexible dosing administration.
Importantly, pharmacodynamic assessments provided evidence of central nervous system activity, including signals associated with enhanced alertness and improved information processing. These findings support the compound’s intended mechanism of action and its potential application in cognitive disorders.
Commenting on the milestone, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said, “The successful completion of this study marks another important step in strengthening our neuroscience pipeline. SUVN-I6107 is the fifth internally discovered molecule from our research platform to enter clinical development and reflects our continued commitment to addressing significant unmet needs in CNS disorders. We are encouraged by the data generated and look forward to advancing the program into Phase 2 studies.”
Ramakrishna Nirogi, President and Chief Scientific Officer of Suven Life Sciences, added, “The study incorporated a comprehensive assessment of safety, pharmacokinetics, pharmacodynamics and translational biomarkers. The results provide valuable evidence of CNS activity and establish a strong foundation for future clinical evaluation.”
SUVN-I6107 is a highly selective M1 positive allosteric modulator designed to enhance cognitive function through targeted activation of muscarinic receptors involved in learning and memory processes. Preclinical studies have demonstrated strong efficacy in cognitive models, favorable brain penetration and a broad safety margin.
The advancement of SUVN-I6107 into Phase 2 development further expands Suven Life Sciences’ clinical-stage portfolio, which includes programs targeting Alzheimer’s disease, major depressive disorder, narcolepsy and other neurological conditions. The company expects to present detailed study findings at future scientific conferences and in peer-reviewed publications.
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative treatments for central nervous system disorders. The company has a diversified portfolio of clinical and preclinical assets targeting neurological and psychiatric conditions, supported by proprietary research and intellectual property across major global markets.
